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Background: A practical and simple regimen for all malaria species is needed towards malaria elimination in
Indonesia. It is worth to compare the efficacy and safety of a single dose of artemisinin-naphthoquine (AN) with a
three-day regimen of dihydroartemisinin-piperaquine (DHP), the existing programme drug, in adults with
uncomplicated symptomatic malaria.
Methods: This is a phase III, randomized, open label using sealed envelopes, multi-centre, comparative study
between a single dose of AN and a three-day dose of DHP in Jayapura and Maumere. The modified WHO inclusion
and exclusion criteria for efficacy study were used in this trial. A total of 401 eligible adult malaria subjects were
hospitalized for three days and randomly treated with AN four tablets single dose on day 0 or DHP three to four
tablets single daily dose for three days, and followed for 42 days for physical examination, thick and thin smears
microscopy, and other necessary tests. The efficacy of drug was assessed by polymerase chain reaction (PCR)
uncorrected and corrected.
Results: There were 153 Plasmodium falciparum, 158 Plasmodium vivax and 90 P. falciparum/P. vivax malaria. Mean
of fever clearance times were similar, 13.0 ± 10.3 hours in AN and 11.3 ± 7.3 hours in DHP groups. The mean of
parasite clearance times were longer in AN compared with DHP (28.0 ± 11.7 hours vs 25.5 ± 12.2 hours, p = 0.04).
There were only 12 PCR-corrected P. falciparum late treatment failures: seven in AN and five in DHP groups. The
PCR uncorrected and corrected on day −42 of adequate clinical and parasitological responses for treatment of any
malaria were 93.7% (95% Cl: 90.3–97.2) and 96.3% (95% Cl: 93.6–99.0) in AN, 96.3% (95% Cl: 93.5–99.0) and 97.3%
(95% Cl: 95.0–99.6) in DHP groups. Few and mild adverse events were reported. All the abnormal haematology and
blood chemistry values had no clinical abnormality.
Conclusion: AN and DHP are confirmed very effective, safe and tolerate for treatment of any malaria. Both drugs
are promising for multiple first-line therapy policies in Indonesia.
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Malaria remains a major public health problem. The
World Health Organization (WHO) estimated the number
of reported cases from Indonesia were 2.5 million in 2006
[1]. Most cases were recorded from Papua and East Nusa
Tenggara provinces, where about 300,000 and 70,000 clin-
ical malaria cases were reported annually from its pro-
vinces. To accelerate malaria control, one of the four key
recommended interventions is to give appropriate anti-
malarial drugs with artemisinin-based combination ther-
apy (ACT) for patients with confirmed malaria [1].
Artemisinin was discovered by Chinese scientists in the
1970s. Artemisinin derivatives are the most rapidly acting
and efficacious anti-malarial drugs. These drugs show rapid
absorption and activity against many stages of Plasmodium,
including trophozoites and early sexual forms (gameto-
cytes). Their short elimination half-life (<3.7 hours)
protects them from resistance and their potent and broad
specificity of action reduces gametocyte carriage and infect-
ivity, and reduces the transmission of Plasmodium falcip-
arum. Tolerability of these drugs is also very good [2,3].
This makes artemisinin derivatives the ideal partner drugs.
WHO recommends the use of artemisinins only in com-
bination with another anti-malarial drug to prevent the
occurrence of drug resistance and to address the issue of its
relatively short half-life. ACT is the best therapeutic option
for treating drug-resistant malaria and retarding the devel-
opment of resistance presently [4].
Since 2004, the Indonesian Malaria Control Programme
has chosen a non-fixed dose artesunate-amodiaquine (AA)
as the programme drug for treatment of uncomplicated P.
falciparum, which had widely reported resistant to chloro-
quine, sulphadoxine-pyrimethamine or quinine [5]. AA is
also effective for Plasmodium vivax, safe for all age groups
and relatively cheap. Though combination of AA is palat-
able and given by single daily dose for three days, the com-
pliance is poor because of the number of pills to be
swallowed. This ACT resulted a problem in its wide-scale
implementation. Moreover, there was reported in vitro
amodiaquine cross-resistance with chloroquine [5]. Conse-
quently, the efficacy of AA was varied (78–96%) [6]. To
overcome these problems, other ACT is needed for treat-
ment of any malaria in Indonesia.
Fixed-dose combination of artemether-lumefantrine (AL)
has been registered recently in Indonesia. This ACT was
safe and very effective with a cure rate of 95% for P. falcip-
arum malaria, but its efficacy was modest (43%) for P. vivax
[7]. AL is not a practical regimen because it should be
administered twice daily for three days and given with fatty
food. Moreover, the cost is expensive, >10 US$ per treat-
ment course. A better ACT that would be simple to use, ef-
fective and affordable for all types of malaria is needed to
eliminate malaria in Indonesia.Dihydroartemisinin-piperaquine (DHP) is a fixed-dose
ACT and given single daily dose for three days. Clinical
trials for treatment of uncomplicated malaria proved more
superior compared with the existing fixed-dose AL, and
ACT programme AA in Papua. This ACT is very effective
with cure rates of ≥95% for all malaria and safe [6,7]. DHP
has been used widely as the first-line ACT for more than
two years in Papua. In addition, the cost of DHP is similar
to AA per treatment course. DHP trials in other areas are
needed to collect unexpected adverse events.
Artemisinin-naphthoquine (AN) is a new fixed-dose
ACT. Naphthoquine phosphate is an anti-malarial drug
synthesized by Chinese Academy of Military Medical
Science in late 1980s. Though naphthoquine has a similar
structure to chloroquine, cross-resistance has not yet been
reported. Existing pharmacological data indicate that
naphthoquine is effective against erythrocytic phase of Plas-
modium, even in chloroquine resistance cases. Naphtho-
quine has a longer half-life (276 hours), compared to
chloroquine and mefloquine. It has been shown to be
effective against P. falciparum at doses of 12 mg/kg used
alone or at 400 mg in combination with artemisinin for
adult patients. Naphthoquine appears to be an ideal partner
drug for artemisinin [8].
AN is administered with a single dose of therapy and has
few side effects. Of limited data, AN was reported safe and
effective for both P. falciparum and P. vivax [9,10]. In a
study in Chinese adult subjects, one dose of a fixed-dose ar-
temisinin (1,000 mg)-naphthoquine (400 mg) for treatment
of uncomplicated malaria showed a cure rate of 98% at day
28 in P. falciparum, and 90% at day 56 in P. vivax [11].
More studies should be done to confirm its efficacy, safety,
and tolerability in an enlarge scale and another population.
Indonesia has been committed to eliminate malaria by
year 2030. A clinical trial of AN was conducted to im-
prove compliance and find a practical and simple ACT
for all malaria species. Based on the previous Indonesian
ACT trials, DHP is the best ACT for treatment of un-
complicated malaria in multi-drug resistant areas. There-
fore, a clinical trial of AN was compared to DHP for its
efficacy and safety in Jayapura and Maumere.
Methods
Time and study location
The trial was carried out in 2007–2008 at four hospitals,
three Armed Forces hospitals in Jayapura (Marthen
Indeys/Army, Soedibjo Sardadi/Navy and Bhayangkara/
Police Hospitals), and one public hospital in Maumere (St
Gabriel Hospital).
Study design
The study was a phase III, randomized, open label,
multi-centre, comparative of the efficacy, safety and
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uncomplicated symptomatic P. falciparum, P. vivax or
mixed P. falciparum/P. vivax malaria. This trial was
approved in writing by the Ethics Committee of National
Institute of Health Research and Development, Ministry
of Health (No. LB.03.02/2/449/2007), and the Bureau of
Food and Drug Control (No.PO.01.01.3.1.1682), Republic
of Indonesia.
Sample size
Assuming the failure rates of AN (P1) and DHP (P2)
were 0.1% and 5.0% based on un-published African AN
studies prior a trial and the WHO recommendation for
choosing ACT programme [12]. The study estimated risk
ratio of failure rate was 2% with α (type I error) of 0.05
and power (1-β) of 80% [13]. A minimum sample size
was 166 subjects per treatment group, and adjusted 20%
for follow-up losses and withdrawals. A total 401 sub-
jects were recruited in this trial.
The formula for calculating the sample size as the fol-
lowing [13]
N ¼ 7:85 Rþ 1ð Þ  P2 R2 þ 1
  
= P2 1 Rð Þ2 ¼ 166þ 20% ¼ 200 subjects
N: The sample size of each of the treatment groups
P1:The failure rate in the Arco™ group (0.1%)
P2:The failure rate in the Duo-Cotecxin™ group (5.0%)
R: The risk ratio of treatment failure (P1/P2 = 0.02)
Procedures
The population of this study was adult males and females
aged 15–69 years, body weight 35–75 kg and presenting
with acute, symptomatic, uncomplicated P. falciparum and/
or P. vivax malaria. They were recruited according to the
modified WHO inclusion criteria (absence of severe malnu-
trition, axillary temperature of ≥37.5°C or history of fever in
the last 24 hours, asexual P. falciparum density 1,000–
200,000/μl, P. vivax and other malaria density ≥250/μl, and
ability to swallow oral medication), and exclusion criteria
[severe vomiting, history or evidence of clinically systematic
significant disorders, other febrile conditions, hypersensitiv-
ity or adverse reactions to anti-malarials, history of use of
any other anti-malarial agent within four weeks prior to
start of the study and confirmed by urine test (Dill Glazko
and Lignin tests), and pregnancy or lactating] for thera-
peutic efficacy study [14]. Subject informed consent was
requested prior the study. Subjects who withdrew early
were not replaced.
Eligible subjects were blindly, randomly assigned equally
to one of the two treatment groups using sealed envelopes.
AN (Arco™, Kunming Pharmaceutical Corporation with
Chinese quality standards, one tablet contained 250 mg of
artemisinin and 100 mg of naphthoquine) was administeredfour tablets single dose only. DHP (Duo-Cotecxin™, Holey-
Cotec Pharmaceutical Co.LTd, China, one tablet contained
40 mg of dihydroartemisinin and 320 mg of piperaquine)
was administered three (body weight of ≤60 kg) to four
tablets (body weight of >60 kg) single daily dose for three
days based on dosage of dihydroartemisinin 2–4 mg/kg bw
or piperaquine 16–32 mg/kg bw [6,7]. Subjects were
observed for one hour to ensure that the medications were
not vomited. All subjects were hospitalized for three days
or until fever and parasite had cleared for at least 24 hours,
returned to study site for follow-up at all scheduled visits to
day 42, and they had additional primaquine for radical
treatment on day 42. Subjects with treatment failure were
withdrawn from the study and given a rescue malaria treat-
ment [12]. They had no study investigations performed
thereafter.
Clinical and laboratory assessments
All eligible subjects had medical history and detail demog-
raphy completed at enrolment. A full physical examin-
ation, electrocardiography (ECG) and laboratory tests
(malaria microscopy, haematology, blood chemistry, PCR
genotyping and urinalysis) were performed at baseline (day
0, prior to dose). Limited physical examination was per-
formed during hospitalization (days 1–2) and on follow-up
days (3, 7 14, 21, 28, 35, and 42) and if clinically indicated
as well as adverse events collected each time. A 12-lead
resting ECG was obtained approximately 2 to 4 hours after
study drug administration on day 0–2, and follow up days
7, 28 and 42. Thick and thin smears were examined at
screening, days 0–2 hospitalization: eight hourly, days 3, 7,
14, 21, 28, 35, and 42; haematology and blood chemistry at
days 0, 3, 7, and 28; and blood spot for PCR at days 0 and
42 or failure. Urinalysis was assessed on days 0 and 3.
HCG was tested for women of potential pregnancy at
screening and day 28. Microscopy results were blind
cross-checked by certified microscopists, and treatment
failures were corrected by PCR. PCR was performed for
speciation of plasmodium and genotype of P. falciparum.
There were 3 loci genotype of P. falciparum tested (MSP1,
MSP2 and GLURP) [15]. The primary (P) and nested (N)
primers are as following : MSP1 (P1: 5′CAC ATG AAA
GTT ATC AAG AAC TTG TC3′, P2: 3′GTA CGT CTA
ATT CAT TTG CAC G5′; N1: 5′GCA GTA TTG ACA
GGT TAT GG3′, N2: 3′GAT TGA AAG GTA TTT
GAC5′); MSP2 (P1: 5′GAA GTT AAT TAA AAC ATT
GTC3′, P2: 3′GAG GGA TGT TGC TGC TCC ACA
G5′, N1: 5′CTA GAA CCA TGC ATA TGT CC3′, N2: 3′
GAG TAT AAG GAG AAG TAT G5′) and GLURP (P1:
5′ACA TGC AAG TGT TGA TCC3′, P2: 3′GAT GGT
TTG GGA GTA ACG5′, N1: 5′TGA ATT CGA AGA
TGT TCA CAC TGA AC3′, N2: 3′TGT AGG TAC CAC
GGG TTC TTG TGG5′). To date, there are no recom-
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new infection of P. vivax malaria from P. vivax treatment
failures.
Efficacy assessment
The efficacy of AN and DHP was assessed in intent-to-
treat (ITT), modified ITT, and evaluable or per-protocol
(PP) population. ITT population included all randomized
subjects who had received any amount of study medica-
tion. Modified ITT population only included correctly
randomized subjects in analysis, and excluded wrongly
randomized and those lost to follow-up [16]. PP analysis
consisted only of the efficacy evaluable (EE) subjects
defined according to the 2003 WHO criteria [14] and
constituted as PP population that did not include sub-
jects who failed to comply with per-protocol.
The efficacy was a proportion of subjects with PCR-
corrected adequate clinical and parasitological response
(ACPR) at day 42. ACPR was defined as the absence of
asexual parasitaemia on day 42 irrespective of the
temperature and not meeting any of criteria of early treat-
ment failure (ETF) or late clinical or parasitological failure
(LCF or LPF), or as subjects with clearance of asexual
parasitaemia within 42 days of initiation of study treat-
ment. Subjects classified as failures by clinical and para-
sitological criteria were considered ACPR if the PCR
analysis showed a new infection (all the alleles in parasites
from the failure-treatment sample were different from
those in the admission sample, for one or more loci tested)
rather than a recrudescence . Recrudescence was defined
as reappearance of asexual parasites of the same isolate as
initial infection with or without clinical signs, after initial
clearance of parasites from the peripheral blood with posi-
tive blood smear and PCR confirmation of the same isolate
(presence of at least one matching alleles) [15]. The early
and late failures were classified according to the 2003
WHO guidelines. The total treatment failure was defined
as the sum of early and late treatment failures [14].
Safety assessment
The safety population was defined as all randomized
subjects who had received any amount of study medica-
tion. Safety was assessed through direct questioning,
physical examinations, ECG abnormalities (prolongation
QT- interval), and significant change from baseline clin-
ical laboratory parameters [17]. Adverse events were fol-
lowed up until the event had resolved.
Data analysis
Data were double entered and validated including micro-
scopic validation and PCR corrected treatment failure
data using EpiData 3.02, and analysed using SPSS for
Windows version 15. The Mann–Whitney U-test was
used for non-parametric comparisons, and Student’s t-test for parametric comparisons. Proportions were exam-
ined using χ2 with Yates’ correction or by Fisher’s exact-
test. The efficacy was assessed by survival analysis in
which the cumulative risk of failure was calculated by
the Kaplan Meier product limit formula.
Results
Baseline characteristics of study subjects
In Jayapura, over 3,000 clinical malaria cases had been
screened, only 301 could be enrolled for this trial, and 151
cases were treated with AN and 150 treated with DHP. In
Maumere, of a total 154 screened clinical malaria, only
100 cases could participate, 50 were treated with AN and
the other 50 treated with DHP. The Armed Forces Hospi-
tals contributed to 75% sample size, so were mostly male
subjects. There were seven subjects had weight >75 kgs
(four in AN and three in DHP), 56% with axillary
temperature of ≥37.5°C. The characteristics of study sub-
jects in both treatment groups were not different (Table 1).
The clinical symptoms of subjects in AN and DHP
groups were also not different. Fever, nausea, headache and
rigors were the common symptoms documented in this
study. Other classical symptoms are shown on Figure 1.
The initial laboratory findings of haematology, blood
chemistry, and parasitology showed no differences be-
tween AN and DHP groups (Table 2). Though some of the
study subjects had abnormal values, only a few had signifi-
cant clinical abnormalities. The distribution of malaria
subjects with anaemia (Hb< 11 g/dL), thrombocytopaenia
(platelet< 150,000/ul) or leucocytosis (>10,000/ul) were
almost similar between the treatment groups (52.2% vs
47.8%, 71.6% vs 73%, 6% vs 5%). Overall, only pallor was
documented as a significant clinical abnormality with ab-
normal values of haematology.
Some study subjects had higher or lower values of
blood chemistry, such as alanine aminotransferase (ALT)
(23.4%), aspartate aminotransferase (AST) (25.9%), bili-
rubin (31.4%), albumin (44.6%), urea (5.7%), sodium
(23.1%), potassium (25.9%), creatinine (28.2%), and
chloride (32.6%). Only jaundice was documented as a
significant clinical abnormality with abnormal values of
bilirubin.
There were 153 Plasmodium falciparum (Pf ), 158
Plasmodium vivax (Pv) and 90 P.falciparum/P.vivax
malaria (Figure 2). Gametocyte carriages were detected
34.4% (52 of 151) in P. falciparum, 94.3% (148 of 157) in
P. vivax and 82.2% (74 of 90) in mixed P.falciparum/
P. vivax, respectively. The range of gametocyte densities
was 1–2,697/ul (Table 2).
Analysed population
The ITT (401), modified ITT (384) and PP (378) popula-
tion in each treatment group were microscopically cross-
checked. There were three of 401 study subjects not






Number of subjects 201 200 401
Age:mean ± SD (range) years 27.6 ± 10.8 (15–69) 26.2 ± 9.2 (15–67) 0.18 26.9 ± 10.0 (15–69)
Body weight: mean ± SD (range) kgs 58.7 ± 8.5 (36–81) 58.5 ± 8.5 (37–85) 0.86 58.6 ± 8.5 (36–85)
Axillary temperature: mean ± SD (range) °C 37.9 ± 1.0 (36–40.3) 37.9 ± 1.1 (35–40.2) 0.84 37.9 ± 1.1 (35–40.3)
Blood Pressure Systole: mean ±
SD (range) mmHg
113 ± 13 (90–150) 114 ± 13 (80–170) 0.44 113 ± 13 (80–170)
Diastole: mean ± SD (range) mmHg 72 ± 9 (50–92) 73 ± 9 (40–120) 0.39 72 ± 9 (40–120)
Heart rate: mean ± SD (range) per min 86 ± 13 (52–126) 87 ± 13 (56–126) 0.59 86± 13 (52–126)
Respiration rate: mean ± SD (range) per min 20 ± 3 (16–36) 20 ± 3 (16–32) 0.51 20± 3.0 (16–36)
Sex: male:female (%) 181:20 (90:10) 170:30 (85:15) 0.17 351:50 (87.5:12.5)
History of fever in the last 24 hours (%) 195 (97.0) 199 (99.5) 0.12 394 (98.3)
Study subject with T.axillary ≥37.5°C (%) 114 (56.7) 109 (54.5) 0.73 223 (55.6)
History of experience malaria in
the last year (%)
160 (79.6) 159 (79.5) 1.00 319 (79.6)
Frequency of malaria in the last year:
mean ± SD (range) times
2.6 ± 2.3 (1–20) 2.4 ± 1.6 (1–12) 0.53 2.7 ± 3 (1–20)
History of taken antimalarial drugs
in the last 4 weeks (%)
































Figure 1 Proportions of malaria symptom and sign on enrolment in artemisinin-naphthoquine (AN) versus dihydroartemisinin-
piperaquine (DHP) groups were no significant difference (p> 0.05).
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Number of subjects 201 200 401
Haematocrit: mean ± SD (range)% 36.1 ± 7.1 (15.5–68.9) 36.6 ± 6.6 (19.1–63.4) 0.46 36.4 ± 6.8 (15.5–68.9)
Haemoglobin: mean ± SD (range) g/dL 12.5 ± 2.3 (6.2–23.1) 12.6 ± 2.1 (6.6–21.1) 0.67 12.6 ± 2.2 (6.2–23.1)
Red Blood Cell: mean ± SD (range) per uL 4.5 ± 0.8 (1.5–7.7) 4.4 ± 0.8 (2.2–7.3) 0.70 4.4 ± 0.8 (1.5–7.7)
Platelet: mean ± SD (range) 103/mm3 116.4 ± 68.7 (1.8–381.0) 116.5 ± 65.9 (1 .0–601.0) 0.98 116 ± 67.2 (1.0–601.0)
White Blood Cell: mean ± SD (range) per uL 6.4 ± 2.2 (2.0–14.0) 7.1 ± 6.0 (2.2–65.0) 0.11 6.8 ± 4.5 (2.0–65.0)
Bilirubin: mean ± SD (range) mg/dL 1.0 ± 0.6 (0.1–5.2) 1.0 ± 0.5 (0.1–3.8) 0.67 1.0 ± 0.5 (0.1–5.2)
Albumin: mean ± SD (range) g/dL 4.1 ± 1.0 (2.0–7.4) 4.2 ± 1.0 (2.2–6.2) 0.25 4.2 ± 1.0 (2.1–7.4)
ALT (SGPT): mean ± SD (range) IU/L 28.8 ± 13.0 (5–73) 28.3 ± 14.2 (6.9–98.0) 0.71 28.5 ± 13.9 (5.0–98.0)
AST (SGOT): mean ± SD (range) IU/L 29.4 ± 14.0 (2.0–87.0) 28.5 ± 11.8 (2.6–91.0) 0.49 28.9 ± 12.9 (2.0–91.0)
Creatinine: mean ± SD (range) mg/dL 1.0 ± 0.4 (0.2–2.5) 0.9 ± 0.3 (0.2–2.0) 0.15 0.9 ± 0.4 (0.2–2.5)
Urea: mean ± SD (range) mg/dL 27.5 ± 11.7 (2.7–80.0) 27.6 ± 11.7 (8.6–110.0) 0.94 27.6 ± 11.7 (2.7–110.0)
Density of asexual parasites: geometric
mean (range) per uL
6310 (304–113550) 6972 (372–140084) 0.21 6634 (304–140084)
Gametocyte carriages (%) 134 (67.3) 140 (70.3) 0.54 274 (68.8)
Density of gametocytes: geometric
mean (range) per uL




Pf =79, Pv =80, PfPv=42 
DHP (N=200)
Pf =74, Pv =78, PfPv=48
Withdrawn
N=10 (5%) 
Pf =4, Pv =4, PfPv=2
Protocol Violation
 N=3 (1.5%) 
Pf =2, Pv =1 
Lost of follow up 
N=7 (3.5%) 




 N=191 (95%) 
Pf =75, Pv =76, PfPv=40
Withdrawn
N=13 (6.5%) 
Pf =6, Pv =6, PfPv=1
Completed study
 N=187 (93.5%) 
Pf =68, Pv =72, PfPv=47
Protocol Violation
 N=0
Lost of follow up 
N=10 (5%)
Pf =5, Pv =4, PfPv=1
Withdrawn consent
N=3 (1.5%) 
Pf =1, Pv =2
Total screened
N=3154
Figure 2 Clinical trial profile of artemisinin-naphthoquine (AN) versus dihydroartemisinin-piperaquine (DHP) groups.
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were in AN group (two P. falciparum cases having asex-
ual parasitaemia <1,000/ul, and one P. vivax case had
taken an anti-malarial drug/chloroquine prior to the
study). While all three withdrew consent, the cases were
in DHP group (one parasitaemic P. falciparum case on
day 0, one withdrawn P. vivax case by family of subject
on day 0, and the one P. vivax case felt discomfort and
dizzy by day 4). During the follow up, 17 cases were
documented lost to follow up, seven (two P. falciparum
cases on days 14 and 35; three P. vivax cases on days 3,
21, and 22; and two mixed P. falciparum/P. vivax cases
on days 7 and 42) in AN group, and 10 [five P. falcip-
arum cases on days 3, 7, 15, 20, and 21; four P. vivax
cases on days 3 (two), 21, and 22; and one mixed P. fal-
ciparum/P. vivax case on day 3)] in DHP group (Figure 2
and Table 3).
Therapeutic efficacy
Both study drugs had rapid fever clearance. Over 90% of
study subjects became afebrile by the first 16 hours after
the first dose of treatment, and all cleared in 56 hours
(Figure 3). The mean of fever clearance times (FCTs)
were 13.0 ± 10.3 hours in AN and 11.3 ± 7.3 hours in
DHP groups, and did not significantly differ.
Almost all hospitalized study subjects (>80%) were
asymptomatic when discharged. During study follow-up,
only mild reported symptoms (headache, dizzy, cough,
abdominal pain, myalgia, sleeping disturbance, and
fatigue) resolved with or without a simple symptomatic
treatment.
Most subjects (>90%) had cleared asexual parasitaemia
by day 1–16 hours (Figure 4). AN had longer mean of
parasite clearance time (PCT: 28.0 ± 11.7 hours) com-
pared with DHP groups (25.5 ± 12.2 hours) (p = 0.04).
Overall, mean of PCT of these ACTs was 26.7 (8–72)
hours.
There was 68.8% gametocyte carriages prior ACT
treatment. However, the proportion of gametocyte car-
riages reduced by day of follow-up. It became 28.7% and
25.8% in the first 24 hours post-treatment, and 18.6%
and 17% by day 3 in AN and DHP groups, respectively.
Gametocyte carriage was still detected in 1.1% subjects
on completion of the study on day 42.
Of 401 randomized study subjects, there were 19 TFs,
12 in AN and seven in DHP groups. No ETF was reported.
There were six documented as LCFs and 13 as LPFs
(Table 3). All the TF cases were from Jayapura, four P. fal-
ciparum, three P. vivax and 12 P. falciparum/P. vivax mal-
aria. Only three of 19 TFs occurred by day ≤28, two in the
AN and one in the DHP group. PCR speciation of the 19
paired samples of TF cases showed three LPFs diagnosed
as P. vivax (one in AN group by day 32 and two in DHP
by day 35) detected as P. falciparum, and classified asprotocol violation cases. There were another two LPFs by
days 35 and 42 diagnosed as P. falciparum, one LPF by
day 35 as mixed P. falciparum/P. vivax, and another one
LCF by day 42 as mixed P. falciparum/P. vivax detected as
P. falciparum new infections in AN group, Of the four TFs
detected as new infections, two TFs had been treated with
quinine plus doxycycline and classified as protocol viola-
tions at day 35. The PCR-corrected treatment outcomes
are shown in Table 4.
The overall uncorrected and corrected PCR therapeutic
efficacies of both ACT for any malaria were between 89%
to 95% in ITT and modified ITT population, and 94% to
97% in PP population. DHP had slightly higher uncor-
rected and corrected PCR at day 42 ACPR (96.3% and
97.3%) compared to AN (93.7% and 96.3%) for treatment
of any malaria (Tables 3 and 4). All TFs’ PCR-corrected
differences were detected in >28 day. Therefore, the day
28 uncorrected and corrected ACPR were similar, 95.5%
(192 of 201) and 93.0% (186 of 200) in AN and DHP ITT
populations; 98.0% (192 of 196) and 97.9% (186 of 190) in
AN and DHP modified ITT population; 99.0% (192 of
194) and 99.5% (186 of 187) in AN and DHP PP popula-
tion. Figures 5, 6 and 7 show the survival curves of PCR-
corrected cumulative risk of failures of AN and DHP for
treatment of any malaria in ITT, modified ITT and PP
population. The hazard ratio of risk failures were no differ-
ent between treatment groups in the three populations.
Safety
There were no serious adverse events reported in malaria
subjects treated with AN and DHP during the study.
Only few (<10%) and mild symptoms as adverse events
were documented. The common reported adverse events
were headache, dizzy, and cough. There were also no
clinically significant effects on myocardial electrophysi-
ology identified through a series of ECG examinations.
In both study groups, haemoglobin, haematocrit, red
blood cell (RBC) and platelet counts were gradually
increased to normal limit by day 28. Means of haemato-
crit and RBC were slightly decreased on day 3, and 7,
and became normal by day 28. In contrast, means of
platelet on days 3 and 7 were increased significantly and
then slightly decreased to normal value by day 28. The
means of haematocrit, Hb, RBC, WBC and platelet at
point of investigation were not statistical significant dif-
ferent between treatment groups. Only few leucocytosis
(5.5%) were found in this trial. Interestingly, there were
21.4% eosinophilia (eosinophil >3%) on day 0, and
increased to 38.5% by day 28. All the abnormal haemato-
logical values had no significant clinical abnormality.
There were mild liver impairment with or without mild
renal impairment on day 0 however bilirubin, albumin,
ALT, AST, creatinine, urea and electrolytes were grad-
ually improved to normal limit by day 28 in malaria






ACPR/Treatment Success (%, 95% CL)
ITT 179 [89.1 (84.7–93.4)] 180 [90.0 (85.8–94.2)] 0.76 359 [89.5 (86.1–92.3)]
Modified ITT 179 [92.3 (88.5–96.0)] 180 [94.7 (91.6–97.9)] 0.33 359 [93.5 (90.5–95.7)]
Per Protocol 179 [93.7 (90.3–97.2)] 180 [96.3 (93.5–99.0)] 0.26 359 [95.0 (92.3–96.9)]
Late Clinical Failure-LCF (%, 95% CL)
ITT 5 [2.5 (0.3–4.6)] 1 [0.5 (0.5–1.5)] 0.10 6 [1.5 (0.6–3.2)]
Modified ITT 5 [2.6 (0.3–4.8)] 1 [0.5 (0.5–1.6)] 0.10 6 [1.6 (0.6–3.4)]
Per Protocol 5 [2.6 (0.4–4.9)] 1 [0.5 (0.5–1.6)] 0.10 6 [1.6 (0.6–3.4)]
Late Parasitological Failure-LPF (%, 95% CL)
ITT 7 [3.5 (0.9–6.0)] 6 [3.0 (0.6–5.4)] 0.78 13 [3.2 (1.7–5.5)]
Modified ITT 7 [3.6 (1.0–6.2)] 6 [3.2 (0.7–5.6)] 0.81 13 [3.4 (1.8–5.7)]
Per Protocol 7 [3.7 (1.0–6.3)] 6 [3.2 (0.7–5.7)] 0.81 13 [3.4 (1.8–5.8)]
“Other Failures” (%, 95% CL)
ITT 10 [5.0 (2.0–8.0)] 13 [6.5 (3.1–9.9)] 0.51 23 [5.7 (3.7–8.5)]
Modified ITT 3 [1.5 (0.2–3.3)] 3 [1.6 (0.2–3.4)] 0.98 6 [1.6 (0.6–3.4)]
Per Protocol 0 0 0
All protocol violations, withdrawn consents, and lost to follow up were classified as “other failures” in ITT analysis.
All protocol violations and withdrawn consents were classified as “other failures” in modified ITT analysis.
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Percent of afebrile subjects
Point of observati
Figure 3 Proportions of afebrile malaria subject treated with artemisi
(DHP) groups were similar by point of observation (p> 0.05).Discussion
ACT is recommended to be given for 3 days when given



















D0-0hr D0-8hr D0-16hr D1-0hr D1-8hr D1-16hr D2-0hr D2-8hr D2-16hr D3-0
AN
DHP
Percent of aparasitaemic subjects
Point of observation Day-hr
Figure 4 Proportions of aparasitaemic (asexual) malaria subject treated with artemisinin-naphthoquine (AN) versus dihydroartemisinin-
piperaquine (DHP) groups were significantly difference by Day 0–16 hr (21.8% vs 55.6%, p< 0.0001), Day 1–0 hr (57.5% vs 71.3%,
p =0.01), and Day 1–8 hr (79.8% vs 88.5%, p= 0.03).
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http://www.malariajournal.com/content/11/1/153regimen, the artemisinin component is present in body
during only two asexual parasite life-cycles, except for
Plasmodium malariae. In each asexual cycle, artemisinin
and its derivatives reduce parasite numbers by a factor ofTable 4 PCR corrected efficacy of AN vs Duocotecxin in all ma
Outcome Artemisinin-
naphthoquine (AN
ACPR/Treatment Success (%, 95% CL)
ITT 181 [90.0 (85.9–94.2
Modified ITT 181 [93.3 (89.8–96.8
Per Protocol 181 [96.3 (93.6–99.0
Late Clinical Failure-LCF (%, 95% CL)
ITT 4 [2.0 (0.1–3.9)]
Modified ITT 4 [2.1 (0.1–4.1)]
3. Per Protocol 4 [2.1 (0.1–4.2)]
Late Parasitological Failure-LPF (%, 95% CL)
ITT 3 [1.5 (0.2–3.2)]
Modified ITT 3 [1.6 (0.2–3.3)]
Per Protocol 3 [1.6 (0.2–3.4)]
“Other Failures” (%, 95% CL)
ITT 13 [6.5 (3.1–9.9)]
Modified ITT 6 [3.1 (0.7–5.5)]
Per Protocol 0
All protocol violations, withdrawn consents, and lost to follow up were classified as
All protocol violations and withdrawn consents were classified as “other failures” in
recurrences.approximately 10,000 [2,12]. This anti-malarial drug is a
potent and rapidly acting blood schizontocide, and
gametocytocide [5,7]. It is still rational to study one-day





)] 180 [90.0 (85.8–94.2)] 0.99 361 [90.0 (86.7–92.8)]
)] 180 [94.7 (91.6–97.9)] 0.55 361 [94.0 (91.1–96.2)]
)] 180 [97.3 (95.0–99.6)] 0.58 361 [96.8 (94.4–98.3)]
1 [0.5 (0.5–1.5)] 0.18 5 [1.2 (0.4–2.9)]
1 [0.5 (0.5–1.6)] 0.18 5 [1.3 (0.4–3.0)]
1 [0.5 (0.5–1.6)] 0.18 5 [1.3 (0.4–3.1)]
4 [2.0 (0.1–3.9)] 0.70 7 [1.7 (0.7–3.6)]
4 [2.1 (0.1–4.1)] 0.68 7 [1.8 (0.7–3.7)]
4 [2.2 (0.1–4.3)] 0.69 7 [1.9 (0.8–3.8)]
15 [7.5 (3.8–11.1)] 0.68 28 [7.0 (4.7–9.9)]
5[2.6 (0.4–4.9)] 11 [2.9 (1.4–5.1)]
0 0.79 0
“other failures” in ITT analysis.
modified ITT analysis. PCR corrected was carried out only for P.falciparum
Log rank Mantel Cox 
P value =0.95 
Figure 5 Cumulative risk of failure of artemisinin-naphthoquine (AN) versus dihydroartemisinin-piperaquine (DHP) in ITT population
infected with any malaria. The TF by day 28 and 42 were 4.5% (9 of 201) and 10% (20 of 201) in AN group, and 7% (14 of 200) and 10% (20 of
200) in DHP group. The hazard ratio of failure between AN and DHP groups was 0.98 (95% CI: 0.53–1.82) with p = 0.95.
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Moreover, the risk of the development of de novo resist-
ance is increased by the greater time dividing asexual para-
sites are exposed to drugs. This makes the long-term risk
of resistance developing a concern for single dose ACT.
Therefore, this study will be useful to confirm the findings
of other previous studies with different types of one-day
ACT (artesunate-amodiaquine, artesunate-sulphadoxine/
pyrimethamine, or artesunate-mefloquine) [18,19] and in
different geographical settings.
Naphthoquine is a tetra-aminoquinoline, synthetic
blood schizontocide anti-malarial drug. Though this
anti-malarial drug has a similar structure to chloro-
quine, cross-resistance with chloroquine has not yet
been reported. Of the limited clinical studies in China,
naphthoquine in combination with artemisinin given in
a single dose, was effective and safe with cure rates of
97.5% for treatment of P. falciparum malaria by day 28,
and 90.0% for the treatment of P. vivax malaria by day
56 [11]. This preliminary findings is valuable data and a
good start for clarification whether the three-day regi-
men ACT is mandatory.Of the existing forms of ACT which had been studied in
Indonesia, a three-day dihydroartemisinin-piperaquine
(DHP) is the best alternative for the Indonesian ACT
programme. DHP is safe and effective for both P. falcip-
arum and P. vivax malaria. The cure rates of DHP for the
treatment of P. falciparum and P. vivax were reported
95.2% and 92.7%. While the cure rates of AA, the first
ACT programme were only 84% and 53.5% [6]. In
addition, DHP had post treatment prophylactic effect in
high transmission area [7]. DHP is a good comparator for
a trial of a new ACT.
Currently, multiple first-line therapies (MFT) policies
against malaria have been introduced. It was developed in
the context of an evolutionary-epidemiological modelling
framework for malaria resistance. The benefits of using
MFT against malaria yields a better clinical outcome, delay
the emergence and slow the fixation of resistant strains,
and allow a larger fraction of the population to be treated
without trading off future treatment of cases that may be
untreatable because of high resistance levels [20]. Despite
DHP, other forms of ACT should be identified to be
chosen for MFT policies, including AN.
Log rank Mantel Cox 
P value =0.58 
Figure 7 Cumulative risk of failure of artemisinin-naphthoquine (AN) versus dihydroartemisinin-piperaquine (DHP) in PP population
infected with any malaria. The TF by day 28 and 42 were 1% (2 of 194) and 3.7% (7 of 188) in AN group, and 0.5% (1 of 187) and 2.7% (5 of
185) in DHP group. The Hazard ratio of failure between AN and DHP groups was 1.38 (95% CI: 0.44 – 4.35) with p = 0.58.
Log rank Mantel Cox 
P value =0.56 
Figure 6 Cumulative risk of failure of artemisinin-naphthoquine (AN) versus dihydroartemisinin-piperaquine (DHP) in modified ITT
population infected with any malaria. The TF by day 28 and 42 were 2% (4 of 196) and 6.7% (13 of 194) in AN group, and 2.1% (4 of 190) and
5.3% (10 of 190) in DHP group. The hazard ratio of failure between AN and DHP groups was 1.28 (95% CI: 0.56 – 2.92) with p = 0.56.
Tjitra et al. Malaria Journal 2012, 11:153 Page 11 of 14
http://www.malariajournal.com/content/11/1/153
Tjitra et al. Malaria Journal 2012, 11:153 Page 12 of 14
http://www.malariajournal.com/content/11/1/153In this trial, one-day single dose of fixed dose regimen
of AN and three-day regimen of DHP did not result ETF
for treatment of any malaria. All 19 TFs were as LTFs
and reported from Jayapura only. Of the 19 TFs, 63.2%
were related with clinical symptoms and classified as
LCFs. Though 84.2% TFs were occurred by day >28,
only 21.1% TFs (4 of 19) confirmed as new infections
which were detected by days 35 and 42. This findings
support Papua as a highly multidrug resistance area. A
significant bigger number of samples from Jayapura (75%
of a total sample) probably gave a chance detected more
TF cases. Moreover, a relatively small number of new
infections in a moderate-high transmission Papua by
days 35 and 42 could be because of long half-life of both
study drugs AN and DHP which known have post treat-
ment prophylactic effect [6,7]. ACT with a long half-life
partner drug is a good choice for malaria in high trans-
mission area, however there will be also an increased risk
of selecting drug-resistant isolates [21]. Therefore, moni-
toring drug efficacy should be routinely maintained to
detect the spread of drug resistance.
In this trial, both drugs showed very effective for treat-
ment of any malaria. AN and DHP had day-42 PCR cor-
rected ACPR of ≥90% in ITT and modified population,
and >95% in PP population. Moreover, the day-28 and
day-42 ACPRs of AN and DHP were not statistically differ-
ent (p> 0.05). These findings are consistent with previous
efficacy studies of AN for treatment of uncomplicated P.
falciparum malaria in China [11], Myanmar [22] and
Papua New Guinea [23], and DHP for treatment of un-
complicated P.falciparum and P.vivax malaria in Indonesia
[6,7] and for treatment of uncomplicated P.falciparum
malaria in other Asian countries [24-28].
Similarly to other forms of ACT, AN and DHP cleared
fever and asexual parasites rapidly with means FCT 13.0
and 11.3 hours, and PCT 28.0 and 25.5 hours. These find-
ings were similar to the previous studies [6,7,11,22–28].
Both forms of ACT also resulted 66.5% haemoglobin recov-
ery by day 28. The anaemic study subjects with Hb< 11 g%
were significantly decreased from 23.6% and 21.6% prior
treatment and became 5.9% and 9.9% by day 28 in AN and
DHP groups. Though many factors influence the recovery
of haemoglobin, a long half-life of partner drugs naphtho-
quine and piperaquine have an important role to prevent
re-infections or relapses, which might cause anaemia.
Both AN and DHP were well-tolerated, with no signifi-
cant ECG changes identified. Most of the adverse events
were mild and related with symptoms attributable to
malaria. All symptoms were recovered with or without
simple treatment. There were no significant differences
in tolerability between the two study drugs.
In this clinical trial, eosinophilia was found in one third
of study subjects treated with AN or DHP. Several studiesalso reported that pseudoeosinophilia was associated with
malaria infection detected by Sysmex XE-2100 haematol-
ogy analyzer due to the presence of haemozoin-containing
neutrophils [29,30]. Eosinophilia may also represent a nor-
mal late response to malaria infection [31,32]. However, all
eosinophilia subjects had no significant clinically abnor-
mality. There were also slightly elevations of aminotrans-
ferase (ALT and AST) in study subjects treated with AN
and DHP which gradually decreased to normal limit. These
findings were reported similar to Chinese studies [33].
This study has shown the efficacy and safety a single
dose of AN and a three-day dose of DHP for treatment of
any malaria in adult subjects. Further analysis of the effi-
cacy and safety specifically in P. falciparum and P. vivax,
and others malaria should be performed and published to
show the detail of study findings. In addition, there was a
study reported a high cure rate of twice daily one day of
AN (100%) versus AL (98.4%) in African children with P.
falciparum malaria [34]. The dosage used in that study
was based on the children weight groups. Dosage for chil-
dren is crucial and will be safe determined by per kg body
weight [35]. Cost of drug is also important factor for
choosing programme malaria drug. A single dose ACT,
such as AN actually should be cheaper compare with
three-day regimen ACT. Moreover, there are study limita-
tions to extend follow up day to D42 whereas D63 is
recommended for AN with a long half lives, and the small
sample size and consequent loss of power.Conclusions
Both fixed-dose forms of ACT are confirmed very effective,
safe and tolerate for treatment of any malaria in adults, and
meet with the recent WHO recommendation for replacing
ineffective drugs. Their longer post-treatment prophylactic
effect is useful in areas where transmission is intense.
Artemisinin-naphthoquine and dihydroartemisinin-pipera-
quine are promising forms of ACT for MFT policy. Phar-
macokinetic and therapeutic efficacy study in children, and
cost-effectiveness study should be carried out for the safety
and effectiveness of large-scale use.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
We would like to thank the Director Generals and staff of Centre for Health
of Armed Forces and Centre for Health of Police in Jakarta; Health Province
Authorities in East Nusa Tenggara and Papua; Director and staff of Army,
Navy and Police Hospitals in Jayapura; Director and staff of Gabriel
Foundation and Kewapante Hospital in Maumere; Bureau of Drug and Food
Control Republic of Indonesia, Jakarta. Dr. Erna Tresnaningsih, the former
Director of Centre for Biomedical and Pharmaceutical Research and
Development; and Director of Sub-directorate of Malaria and staff, Ministry of
Health, Republic of Indonesia for supporting this clinical trial. We also thank
to Kunming Pharmaceutical Corporation for funding the artemisinin-
naphthoquine trial.
Tjitra et al. Malaria Journal 2012, 11:153 Page 13 of 14
http://www.malariajournal.com/content/11/1/153Author details
1National Institute of Health Research and Development, Ministry of Health,
Jakarta, Indonesia. 2Centre for Biomedical Research and Development,
Jayapura, Papua, Indonesia. 3Marthen Indeys Army Hospital, Jayapura, Papua,
Indonesia. 4Soedibjo Sardadi Navy Hospital, Jayapura, Papua, Indonesia.
5Bhayangkara Police Hospital, Jayapura, Papua, Indonesia. 6Kewapante
Catholic Hospital, Maumere, Sikka, East Nusa Tenggara, Indonesia. 7TC Hillers
District Public Hospital, Maumere, Sikka, East Nusa Tenggara, Indonesia.
Authors’ contributions
ET: study conceptualization and design. ET, ARH, HS, BP, RE, EAY, TP, SL, ES, N,
EY, LY, JL, BW, FA, TADD, AP performed the study. ET, ARH, HS and ES
analysed the data. ET, ARH, ES, T prepared the manuscript. All authors have
read and approved the final manuscript.
Funding
The study was funded by the Kunming Pharmaceutical Corporation.
Received: 28 February 2012 Accepted: 3 May 2012
Published: 3 May 2012
References
1. World Health Organization: World Malaria Report 2008. WHO/HTM/GMP/
2008.1. Geneva: WHO; 2008.
2. World Health Organization: Antimalarial drug combination therapy, Report of
WHO Technical Consultation. WHO/CDS/RBM/2001.35. Geneva: WHO; 2001.
3. Price RN, Nosten F, Luxemburger C, Ter Kuile FO, Paiphun L,
Chongsuphajaisiddhi T, White NJ: Effects of artemisinin derivatives on
malaria transmissibility. Lancet 1996, 347:1654–1658.
4. Nosten F, van Vugt M, Price RN, Luxemburger C, Thway KL, Brockman A,
McGready R, ter Kuile F, Looareesuwan S, White NJ: Effects of artesunate-
mefloquine combination on incidence of Plasmodium falciparum malaria
and mefloquine resistance in western Thailand: a prospective study.
Lancet 2000, 356:297–302.
5. Tjitra E, Gunawan S, Laihad F, Marwoto H, Sulaksono S, Arjoso S, Richie TL,
Manurung N: Evaluation of antimalaria drugs in Indonesia, 1981–1995.
Bull Hlth Studies 1997, 25:27–58.
6. Hasugian AR, Purba HLE, Kenangalem E, Wuwung RM, Ebsworth EP,
Maristela R, Penttinen PMP, Laihad F, Anstey NM, Tjitra E, Price RN:
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior
efficacy and posttreatment prophylaxis against multidrug-resistant
Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 2007,
44:1067–1074.
7. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F,
Ebsworth EP, Anstey NM, Tjitra E, Price RN: Two fixed-dose artemisinin
combinations for drug-resistant falciparum and vivax malaria in Papua,
Indonesia: an open-label randomised comparison. Lancet 2007,
369:757–765.
8. Pang X, Wang G, Xing Q: Hundred one cases Plasmodium falciparum
treated with naphthoquine phosphate. Chinese J Parasitic Disease 1999,
17:20–22.
9. Wang JY, Shan CQ, Fu D: Clinical trial of co-naphthoquine in the
treatment of falciparum malaria. Chin J Parasit Dis Con 2003, 16:135–136.
10. Guo WZ, Zheng Q, Li G, Guo XB: A randomized controlled study of
napthoquine and artesunate in the treatment of falciparum malaria. Journal
of Guangzhou University Traditional Chinese Medicine 2003, 17:235–237.
11. Wang JY, Cao W, Shan CQ, Zhang M, Li GF, Ding DB, Shi YL, Wu BA, AMMS
China: Naphthoquine phosphate and its combination with artemisinin.
Acta Trop 2004, 89:375–381.
12. World Health Organization: Guidelines for the treatment of malaria. WHO/
HTM/MAL/2006.1108. Geneva: WHO; 2006.
13. Schulz KF, Grimes DA: The Lancet Handbook of Essential Concepts in Clinical
Research. Main edition. Edinburg, London, New York, Oxford, Philadelphia, St
Louis, Sydney, Toronto: Elsevier; 2006.
14. World Health Organization: Assessment and monitoring of antimalarial drug
efficacy for the treatment of uncomplicated falciparum malaria, WHO/HTM/
RBM/2003.50. Geneva: WHO; 2003.
15. World Health Organization: Methods and techniques for clinical trials on
antimalarial drug efficacy. Genotyping to identify parasite populations.
Informal consultation organized by the Medicines for Malaria Venture andcosponsored by the World Health Organization. 29–31 May 2007. Amsterdam,
The Netherlands: WHO; 2008.
16. Abraha I, Montedori A: Modified intention to treat reporting in randomized
controlled trials: systematic review. BMJ 2010, 340:c2697. Epub 2010/06/16.
17. Monitoring and Reporting Adverse Events. World Health Organization:
Toxicity Grading Scale for Determining Severity of Adverse Events.: ; 2003.
http://icssc.org/documents/AE%20Manual%202003%20Appendices%
20February_06_2003%20final.pdf.
18. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens F,
Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B,
Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P,
Osimbo P, Rezbach P, Some E, Taylor WRJ: Amodiaquine-artesunate versus
amodiaquine for uncomplicated Plasmodium falciparum malaria in African
children: a randomised, multicentre trial. Lancet 2002, 359:1365–1372.
19. World Health Organization: The use of artemisinin and its derivatives as
antimalarial drugs: report of a joint CTD/DMP/TDR Informal Consultation,
WHO/MAL/98.1086. Geneva: WHO; 1998.
20. Boni MF, Smith DL, Laxminarayan R: Benefits of using multiple first-line
therapies. Proc Natl Acad Sci USA 2008, 105:14216–14221.
21. Watkins WM, Sibley CH, Hastings IM: The search for effective and
sustainable treatment for Plasmodium falciparum malaria in Africa: a
model of the selection of resistance by antifolate drugs and their
combinations. AmJTrop Med Hyg 2005, 72:163–173.
22. Tun T, Tint HS, Lin K, Kyaw TT, Myint MK, Khaing W, Tun ZW: Efficacy of oral
single dose therapy with artemisinin–naphthoquine phosphate in
uncomplicated falciparum malaria. Acta Trop 2009, 111:275–278.
23. Hombhanje FW, Linge D, Saweri A, Kuanch C, Jones R, Toraso S, Geita J, Masta
A, Kevau I, Hiawalyer G, Sapuri M: Artemisinin-naphthoquine combination
(ARCOTM) therapy for uncomplicated falciparum malaria in adults of Papua
New Guinea: a preliminary report on safety and efficacy. Malar J 2009, 8:196.
24. Denis MB, Davis TM, Hewitt S, Incardona S, Nimol K, Fandeur T, Poravuth Y,
Lim C, Socheat D: Efficacy and safety of dihydroartemisinin-piperaquine
(Artekin) in Cambodian children and adults with uncomplicated
falciparum malaria. Clin Infect Dis 2002, 35:1469–1476.
25. Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, Dong THA,
Tran TT, Stepniewska K, White NJ, Farrar J: Dihydroartemisinin-piperaquine
against multidrug-resistant Plasmodium falciparum malaria in Vietnam:
randomized clinical trial. Lancet 2004, 363:18–22.
26. Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W,
Hutagalung R, Wilairatana P, Brockman A, Looareesuwan S, Nosten F, White NJ:
Randomized, controlled dose-optimization studies of dihydroartemisinin-
piperaquine for the treatment of uncomplicated multidrug-resistant
falciparum malaria in Thailand. J Infect Dis 2004, 190:1773–1782.
27. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo APP, Naing AL, Nyo MY,
Myint NZH, Imwong M, Ashley E, Lee SJ, White NJ: Efficacy and
effectiveness of dihydroartemisinin-piperaquine versus artesunate-
mefloquine in falciparum malaria an open-label randomized comparison.
Lancet 2006, 367:2075–2085.
28. Mayxay M, Thongpraseuth V, Khanthavong M, Lindegardh N, Barends M,
Keola S, Pongvongsa T, Phompida S, Phetsouvanh R, Stepniewska K, White
NJ, Newton PN: An open, randomized comparison of artesunate plus
mefloquine vs dihydroartemisinin-piperaquine for the treatment of
uncomplicated Plasmodium falciparum malaria in the Lao People’s
Democratic Republic (Laos). Trop Med Int Health 2006, 11:1157–1165.
29. Davis TM, Ho M, Supanaranond W, Looareesuwan S, Pukrittayakamee S,
White NJ: Changes in the peripheral blood eosinophil count in
falciparum malaria. Acta Trop 1991, 48:243–246.
30. Shanks GD, Wilairatanaporn C: Eosinophilic response to falciparum malaria
infections. Southeast Asian J Trop Med Public Health 1992, 23:795–797.
31. Huh J, Jung J, Yoon H, Chung W: Pseudoeosinophilia associated with
malaria infection determined in the Sysmex XE-2100 hematology
analyzer. Ann Hematol 2005, 84:400–402.
32. Huh HJ, Oh GY, Huh JW, Chae SL: Malaria detection with the Sysmex
XE-2100 hematology analyzer using pseudoeosinophilia and abnormal
WBC scattergram. Ann Hematol 2008, 87:755–759.
33. Wang JY, Sun ZW, Fu DD: Efficacy of naphthoquine, artemisinin and
combination of the two drugs in the treatment of falciparum malaria.
Clin J Parasitic Dis 2003, 21:131–133.
34. Toure OA, Penali LK, Yapi JD, Ako BA, Toure W, Djerea K, Gomez GO, Makaila
O: A comparative, randomized clinical trial of artemisinin/naphtoquine
Tjitra et al. Malaria Journal 2012, 11:153 Page 14 of 14
http://www.malariajournal.com/content/11/1/153twice daily one day versus artemether/lumefantrine six doses regimen in
children and adults with uncomplicated falciparum malaria in Côte
d’Ivoire. Malar J 2009, 8:148.
35. Benyamin J, Moore B, Lee ST, Senn M, Griffin S, Lautu D, Salman S, Siba P,
Mueller I, Davis TM: Artemisinin-naphthoquine combination therapy for
uncomplicated pediatric malaria: a tolerability, safety, and preliminary
efficacy study. Antimicrob Agents Chemother 2012, 56:2465–2471.
doi:10.1186/1475-2875-11-153
Cite this article as: Tjitra et al.: Efficacy and safety of artemisinin-
naphthoquine versus dihydroartemisinin-piperaquine in adult patients
with uncomplicated malaria: a multi-centre study in Indonesia. Malaria
Journal 2012 11:153.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
